Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Asthma

  Free Subscription


Articles published in Eur Respir J

Retrieve available abstracts of 193 articles:
HTML format



Single Articles


    January 2025
  1. DEITEREN A, Krupka E, Bontinck L, Imberdis K, et al
    A proof-of-mechanism trial in asthma with lunsekimig, a bispecific nanobody(R) molecule.
    Eur Respir J. 2025 Jan 30:2401461. doi: 10.1183/13993003.01461-2024.
    PubMed     Abstract available


  2. SOENDERGAARD MB, Hjortdahl F, Hansen S, Bjerrum AS, et al
    Pre-biologic disease trajectories are associated with morbidity burden and biologic treatment response in severe asthma.
    Eur Respir J. 2025 Jan 9:2401497. doi: 10.1183/13993003.01497-2024.
    PubMed     Abstract available


  3. NOLASCO S, Mukherjee M, Nair P
    Trajectories of responses to mepolizumab in severe asthma.
    Eur Respir J. 2025;65:2402023.
    PubMed    



  4. ERJ Podcast January 2025: Treatment response to mepolizumab in severe eosinophilic asthma.
    Eur Respir J. 2025;65:25E6501.
    PubMed    


    December 2024
  5. PIZZICHINI MMM, Pizzichini E
    Is asthma remission an important clinical outcome in asthma management?
    Eur Respir J. 2024;64:2401908.
    PubMed    


  6. OKTELIK FB, Benamar M
    Glycerolipids disrupt regulatory T-cells in asthma.
    Eur Respir J. 2024;64:2401386.
    PubMed    


    November 2024
  7. CHAN AHY, De Keyser HH, Horne R, Szefler SJ, et al
    Defining adherence phenotype and endotypes to personalise asthma management.
    Eur Respir J. 2024 Nov 27:2401357. doi: 10.1183/13993003.01357-2024.
    PubMed    


  8. KHALEVA E, Brightling C, Eiwegger T, Altraja A, et al
    Patient-centred composite scores as tools for assesment of response to biological therapy for paediatric and adult severe asthma.
    Eur Respir J. 2024 Nov 7:2400691. doi: 10.1183/13993003.00691-2024.
    PubMed     Abstract available


  9. POLVERINO F, Woodruff PG
    Radiomultiomics: pioneering precision medicine for severe asthma.
    Eur Respir J. 2024;64:2401639.
    PubMed    


    October 2024
  10. HAMADA Y, Thomas D, Harvey ES, Stevens S, et al
    Distinct trajectories of treatment response to mepolizumab toward remission in patients with severe eosinophilic asthma.
    Eur Respir J. 2024 Oct 10:2400782. doi: 10.1183/13993003.00782-2024.
    PubMed     Abstract available


  11. KERMANI NZ, Chung KF, Macis G, Santini G, et al
    Radiomultiomics: quantitative CT clusters of severe asthma associated with multi-omics.
    Eur Respir J. 2024 Oct 10:2400207. doi: 10.1183/13993003.00207-2024.
    PubMed     Abstract available


  12. MCSORLEY HJ
    RIPK2 inhibition gets the NOD for asthma.
    Eur Respir J. 2024;64:2401372.
    PubMed    


    September 2024
  13. WECHSLER ME, Brusselle G, Virchow JC, Bourdin A, et al
    Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies.
    Eur Respir J. 2024 Sep 26:2400316. doi: 10.1183/13993003.00316-2024.
    PubMed     Abstract available


  14. ZHU Z, Shibata R, Hoffman KL, Cormier J, et al
    Integrated nasopharyngeal airway metagenome and asthma genetic risk endotyping of severe bronchiolitis in infancy and risk of childhood asthma.
    Eur Respir J. 2024 Sep 26:2401130. doi: 10.1183/13993003.01130-2024.
    PubMed     Abstract available


  15. GIBSON PG, McDonald VM
    Integrating hot topics and implementation of treatable traits in asthma.
    Eur Respir J. 2024 Sep 10:2400861. doi: 10.1183/13993003.00861-2024.
    PubMed     Abstract available


  16. LAHOUSSE L
    Overweight and dysanapsis in childhood asthma.
    Eur Respir J. 2024;64:2401164.
    PubMed    


  17. MAKRINIOTI H, Fainardi V, Bonnelykke K, Custovic A, et al
    European Respiratory Society statement on preschool wheezing disorders: updated definitions, knowledge gaps and proposed future research directions.
    Eur Respir J. 2024;64:2400624.
    PubMed     Abstract available


  18. WENZEL SE
    Allergen challenge, eosinophils and the long road to asthma endotypes.
    Eur Respir J. 2024;64:2401316.
    PubMed    


    August 2024
  19. VERSI A, Azim A, Ivan FX, Abdel-Aziz MI, et al
    Host-microbial interactions differ with age of asthma onset.
    Eur Respir J. 2024 Aug 30:2400428. doi: 10.1183/13993003.00428-2024.
    PubMed    


  20. AILI A, Wang Y, Shang Y, Zhang L, et al
    LPG 18:0 is a general biomarker of asthma and inhibits the differentiation and function of regulatory T cells.
    Eur Respir J. 2024 Aug 15:2301752. doi: 10.1183/13993003.01752-2023.
    PubMed     Abstract available


  21. ABDO M, Pedersen F, Kirsten AM, Trinkmann F, et al
    Association of airway inflammation and smoking status with IL-33 level in sputum of patients with asthma or COPD.
    Eur Respir J. 2024 Aug 15:2400347. doi: 10.1183/13993003.00347-2024.
    PubMed    


  22. ALVAREZ-SIMON D, Ait Yahia S, Audousset C, Fanton d'Andon M, et al
    Local Receptor-interacting Protein Kinase 2 inhibition mitigates HDM-induced asthma.
    Eur Respir J. 2024 Aug 8:2302288. doi: 10.1183/13993003.02288-2023.
    PubMed     Abstract available


  23. BLOOM C
    The burden of zoster in asthma: what is left to learn?
    Eur Respir J. 2024;64:2401300.
    PubMed    


  24. KHURANA S, Georas SN
    Stepping down biologics in asthma: is it time to challenge the status quo?
    Eur Respir J. 2024;64:2401168.
    PubMed    


    July 2024
  25. GAUVREAU GM, Sehmi R, FitzGerald JM, Leigh R, et al
    Benralizumab for allergic asthma: a randomised, double-blind, placebo-controlled, trial.
    Eur Respir J. 2024 Jul 26:2400512. doi: 10.1183/13993003.00512-2024.
    PubMed     Abstract available


  26. WILKINSON A, Woodcock A
    High-quality and low-carbon asthma care go hand in hand.
    Eur Respir J. 2024;64:2400638.
    PubMed    


  27. SOUMAGNE T, Degano B
    Real world evidence in asthma: what to expect beyond randomised controlled trials?
    Eur Respir J. 2024;64:2400716.
    PubMed    


  28. LU J, Wang Z
    Mendelian randomisation supports no evidence of the association between asthma and coronary heart disease in East Asians.
    Eur Respir J. 2024;64:2400628.
    PubMed    


    June 2024
  29. MORTIMER KJ, Cruz AA, Sepulveda-Pachon IT, Jorga A, et al
    Global herpes zoster burden in adults with asthma: a systematic review and meta-analysis.
    Eur Respir J. 2024 Jun 20:2400462. doi: 10.1183/13993003.00462-2024.
    PubMed     Abstract available


  30. STIKKER B, Trap L, Sedaghati-Khayat B, de Bruijn MJW, et al
    Epigenomic partitioning of a polygenic risk score for asthma reveals distinct genetically driven disease pathways.
    Eur Respir J. 2024 Jun 20:2302059. doi: 10.1183/13993003.02059-2023.
    PubMed     Abstract available


  31. SAIKUMAR JAYALATHA AK, Ketelaar ME, Hesse L, Badi YE, et al
    IL-33 induced gene expression in activated Th2 effector cells is dependent on IL-1RL1 haplotype and asthma status.
    Eur Respir J. 2024 Jun 6:2400005. doi: 10.1183/13993003.00005-2024.
    PubMed    


  32. VERBANCK S, Eddy RL, McIntosh MJ, Parraga G, et al
    Missing airways, ventilation defects and conductive airway physiology in asthma.
    Eur Respir J. 2024 Jun 6:2400242. doi: 10.1183/13993003.00242-2024.
    PubMed    


  33. SOENDERGAARD MB, Bjerrum AS, Rasmussen LM, Lock-Johansson S, et al
    OPTIMAL: Titration of anti-IL5 biologics in severe asthma - An open label randomised controlled trial.
    Eur Respir J. 2024 Jun 6:2400404. doi: 10.1183/13993003.00404-2024.
    PubMed     Abstract available


  34. MCDOWELL PJ, McDowell R, Busby J, Eastwood MC, et al
    Clinical remission with biologic therapies in severe asthma: a matter of definition.
    Eur Respir J. 2024;63:2400160.
    PubMed     Abstract available


  35. BEASLEY R, Noble J, Weatherall M
    The evidence base for ICS/formoterol maintenance and reliever therapy in severe asthma.
    Eur Respir J. 2024;63:2400523.
    PubMed     Abstract available


    May 2024
  36. KJELDGAARD JENSEN S, Tingskov Pedersen CE, Fischer-Rasmussen K, Elsner Melgaard M, et al
    Genetic predisposition to high BMI increases risk of early life respiratory infections and episodes of severe wheeze and asthma.
    Eur Respir J. 2024 May 29:2400169. doi: 10.1183/13993003.00169-2024.
    PubMed     Abstract available


  37. LIU T, Prescott WG, Zhou X
    Advances in Non-Type 2 Asthma in the Severe Cases: from molecular insights to novel treatment strategies.
    Eur Respir J. 2024 May 2:2300826. doi: 10.1183/13993003.00826-2023.
    PubMed     Abstract available


  38. RAMAKRISHNAN S, Montgomery B, Pavord ID
    Blood eosinophils and lung function loss: from passive prediction to active prevention?
    Eur Respir J. 2024;63:2400812.
    PubMed    


  39. BUSH A, Randerath W, Roche N
    As needed ICS/formoterol: not all of Europe is equal.
    Eur Respir J. 2024;63:2400408.
    PubMed    


  40. HONG YS, Park HY, Ryu S, Shin SH, et al
    The association of blood eosinophil counts and FEV(1) decline: a cohort study.
    Eur Respir J. 2024;63:2301037.
    PubMed     Abstract available


  41. POLVERINO F, Sin DD
    Type 2 airway inflammation in COPD.
    Eur Respir J. 2024;63:2400150.
    PubMed     Abstract available


    April 2024
  42. HATTER L, Holliday M, Eathorne A, Bruce P, et al
    The carbon footprint of as-needed budesonide-formoterol in mild asthma: a post hoc analysis.
    Eur Respir J. 2024 Apr 12:2301705. doi: 10.1183/13993003.01705-2023.
    PubMed     Abstract available


  43. JACKSON DJ, Pelaia G, Emmanuel B, Tran TN, et al
    Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme.
    Eur Respir J. 2024 Apr 4:2301521. doi: 10.1183/13993003.01521-2023.
    PubMed     Abstract available


  44. KRISHNAN JA, Buhl R
    As-needed ICS/formoterol or as-needed SABA in mild asthma?
    Eur Respir J. 2024;63:2302308.
    PubMed    


  45. PAPI A, Ferreira DS, Tonia T, Schleich F, et al
    Response from the authors: As-needed ICS/formoterol or as-needed SABA in mild asthma?
    Eur Respir J. 2024;63:2400395.
    PubMed    


  46. STANESCU C, Talarico R, Weichenthal S, Villeneuve PJ, et al
    Early life exposure to pollens and increased risks of childhood asthma: a prospective cohort study in Ontario children.
    Eur Respir J. 2024;63:2301568.
    PubMed     Abstract available


  47. VARRICCHI G, Brightling CE, Grainge C, Lambrecht BN, et al
    Airway remodelling in asthma and the epithelium: on the edge of a new era.
    Eur Respir J. 2024;63:2301619.
    PubMed     Abstract available


  48. BLOOM CI
    Reply: Asthma and cardiovascular disease: the strength of triangulation.
    Eur Respir J. 2024;63:2400554.
    PubMed    


  49. TATTERSALL MC, Gangnon RE, Jarjour NN
    Asthma and cardiovascular disease: embracing disease heterogeneity is required.
    Eur Respir J. 2024;63:2400469.
    PubMed    



  50. ERJ Podcast April 2024: Allergic bronchopulmonary aspergillosis.
    Eur Respir J. 2024;63:24E6304.
    PubMed    


    March 2024
  51. LIU T, Liu S, Rui X, Cao Y, et al
    Gasdermin B, an asthma-susceptibility gene, promotes MAVS-TBK1 signaling and airway inflammation.
    Eur Respir J. 2024 Mar 21:2301232. doi: 10.1183/13993003.01232-2023.
    PubMed     Abstract available


  52. LUO RG, Wu YF, Lu HW, Weng D, et al
    Th2-skewed peripheral T helper cells drives B cells in allergic bronchopulmonary aspergillosis.
    Eur Respir J. 2024 Mar 21:2400386. doi: 10.1183/13993003.00386-2024.
    PubMed     Abstract available


  53. RUSSELL RJ, Boulet LP, Brightling CE, Pavord ID, et al
    The airway epithelium: an orchestrator of inflammation, a key structural barrier and a therapeutic target in severe asthma.
    Eur Respir J. 2024 Mar 7:2301397. doi: 10.1183/13993003.01397-2023.
    PubMed     Abstract available



  54. "Asthma and incident coronary heart disease: an observational and Mendelian randomisation study." C.A. Valencia-Hernandez, F. Del Greco M, V. Sundaram, et al. Eur Respir J 2023; 62: 2301788.
    Eur Respir J. 2024;63:2351788.
    PubMed    



  55. "Aberrant anti-viral response of natural killer cells in severe asthma." J. Devulder, C. Chenivesse, V. Ledroit, et al. Eur Respir J 2020; 55: 1802422.
    Eur Respir J. 2024;63:1852422.
    PubMed    


    February 2024
  56. WANG T, Duan W, Jia X, Huang X, et al
    Associations of combined phenotypic ageing and genetic risk with incidence of chronic respiratory diseases in the UK Biobank: a prospective cohort study.
    Eur Respir J. 2024;63:2301720.
    PubMed     Abstract available


    January 2024
  57. ZHU Z
    Early-life airway microbiome and childhood asthma development.
    Eur Respir J. 2024;63:2302187.
    PubMed    


  58. HOGMAN M, Bowerman C, Chavez L, Dressel H, et al
    ERS technical standard: Global Lung Function Initiative reference values for exhaled nitric oxide fraction (F (ENO(50)) ).
    Eur Respir J. 2024;63:2300370.
    PubMed     Abstract available



  59. ERJ Podcast January 2024: The microbiome in early life and childhood asthma.
    Eur Respir J. 2024;63:24E6301.
    PubMed    


    December 2023
  60. SUNDE RB MD PHD, Thorsen J MD PhD, Kim M MSc PhD, Schoos AM MD PhD, et al
    Bacterial Colonization of the Airway in Neonates and Risk of Asthma and Allergy Until Age 18 Years.
    Eur Respir J. 2023 Dec 14:2300471. doi: 10.1183/13993003.00471-2023.
    PubMed     Abstract available


  61. BEASLEY R, Noble J, Weatherall M
    Clinical remission with biologic therapies in severe asthma: a matter of definition.
    Eur Respir J. 2023;62:2301844.
    PubMed    


  62. WECKMANN M, Reddy KD
    Epigenome-wide association studies: the exposures of yesterday form the methylations of tomorrow.
    Eur Respir J. 2023;62:2301552.
    PubMed    


    November 2023
  63. CIVIDINI S, Sinha I, Donegan S, Maden M, et al
    Best step-up treatments for children with uncontrolled asthma: A systematic review and network meta-analysis of individual participant data.
    Eur Respir J. 2023 Nov 9:2301011. doi: 10.1183/13993003.01011-2023.
    PubMed     Abstract available


  64. VALENCIA-HERNANDEZ CA, Del Greco M F, Sundaram V, Portas L, et al
    Asthma and incident coronary heart disease: an observational and Mendelian randomisation study.
    Eur Respir J. 2023 Nov 9:2301788. doi: 10.1183/13993003.01788-2023.
    PubMed     Abstract available


  65. SORIANO JB, Polverino F
    Sex and gender in COPD and asthma.
    Eur Respir J. 2023;62:2301505.
    PubMed    


  66. MORGAN C, Higbee D
    An attack of asthma is not an attack of the heart: clarifying causal links between asthma and incident coronary heart disease.
    Eur Respir J. 2023;62:2302009.
    PubMed    


    October 2023
  67. MCDOWELL PJ, McDowell R, Busby J, Eastwood MC, et al
    Clinical remission in severe asthma with Biologic Therapy: an analysis from the UK Severe Asthma Registry.
    Eur Respir J. 2023 Oct 19:2300819. doi: 10.1183/13993003.00819-2023.
    PubMed     Abstract available


  68. HERRERA-LUIS E, de la Rosa-Baez C, Huntsman S, Eng C, et al
    Novel insights into the whole blood DNA methylome of asthma in ethnically diverse children and youth.
    Eur Respir J. 2023 Oct 6:2300714. doi: 10.1183/13993003.00714-2023.
    PubMed     Abstract available



  69. October Podcast: ERS short guidelines for the use of as-needed ICS/formoterol in mild asthma.
    Eur Respir J. 2023;62:23E6204.
    PubMed    


    September 2023
  70. FIOCCHI AG, Phipatanakul W, Zeiger RS, Durrani SR, et al
    Dupilumab leads to better-controlled asthma & quality of life in children: the VOYAGE study.
    Eur Respir J. 2023 Sep 21:2300558. doi: 10.1183/13993003.00558-2023.
    PubMed     Abstract available


  71. PAPI A, Ferreira DS, Agache I, Baraldi E, et al
    European Respiratory Society Short Guidelines for the use of as-needed ICS/formoterol in mild Asthma.
    Eur Respir J. 2023 Sep 7:2300047. doi: 10.1183/13993003.00047-2023.
    PubMed     Abstract available


  72. FARINHA I, Heaney LG
    Defining trajectory in severe asthma: can it be changed?
    Eur Respir J. 2023;62:2301281.
    PubMed    


    August 2023
  73. VON BULOW A, Hansen S, Sandin P, Ernstsson O, et al
    Severe asthma trajectories in adults: findings from the NORDSTAR cohort.
    Eur Respir J. 2023 Aug 24:2202474. doi: 10.1183/13993003.02474-2022.
    PubMed     Abstract available


  74. POWELL WT, Reeves SR
    From small to big, using microRNA profiling to investigate infant origins of childhood asthma.
    Eur Respir J. 2023;62:2301052.
    PubMed    


  75. OSADNIK CR, Brighton LJ, Burtin C, Cesari M, et al
    European Respiratory Society statement on frailty in adults with chronic lung disease.
    Eur Respir J. 2023;62:2300442.
    PubMed     Abstract available



  76. ERJ Podcast August 2024: Titration of anti-IL-5 biologics in severe asthma.
    Eur Respir J. 2024;64:24E6402.
    PubMed    


    July 2023
  77. CAZZOLA M, Page CP, Matera MG, Rogliani P, et al
    Revisiting Asthma Pharmacotherapy: Where Do We Stand and Where Do We Want to Go?
    Eur Respir J. 2023 Jul 20:2300700. doi: 10.1183/13993003.00700-2023.
    PubMed     Abstract available


  78. NANZER AM, Taylor V, Hearn AP, Kavanagh JE, et al
    The impact of steroid-sparing biologic therapies on weight loss in obese individuals with severe eosinophilic asthma.
    Eur Respir J. 2023 Jul 20:2300245. doi: 10.1183/13993003.00245-2023.
    PubMed    


    June 2023
  79. ZHU Z, Freishtat RJ, Harmon B, Hahn A, et al
    Nasal airway microRNA profiling of infants with severe bronchiolitis and risk of childhood asthma: A multicenter prospective study.
    Eur Respir J. 2023 Jun 15:2300502. doi: 10.1183/13993003.00502-2023.
    PubMed     Abstract available


  80. DUIJTS L
    Prematurity-related chronic respiratory disease across the life course.
    Eur Respir J. 2023;61:2300662.
    PubMed    


  81. VAN DER VEER T, de Koning Gans JM, Braunstahl GJ, Pieters A, et al
    The effect of beclomethasone-formoterol versus placebo on chronic cough in patients with non-CF bronchiectasis: the FORZA randomised-controlled trial.
    Eur Respir J. 2023 Jun 1:2300186. doi: 10.1183/13993003.00186-2023.
    PubMed    


    April 2023
  82. EIWEGGER T, Bendien SA
    Defining the questions to be asked in severe asthma trials: data from the COMSA working group.
    Eur Respir J. 2023;61:2202058.
    PubMed    


    March 2023
  83. PULAKKA A, Risnes K, Metsala J, Alenius S, et al
    Preterm birth and asthma and COPD in adulthood: a nationwide register study from two Nordic countries.
    Eur Respir J. 2023 Mar 29:2201763. doi: 10.1183/13993003.01763-2022.
    PubMed     Abstract available


  84. MAHMOUD O, Granell R, Peralta GP, Garcia-Aymerich J, et al
    Early-life and health behaviour influences on lung function in early adulthood.
    Eur Respir J. 2023;61:2001316.
    PubMed     Abstract available


  85. CHARRIOT J, Ahmed E, Bourdin A
    Local targeting of TSLP: feat or defeat.
    Eur Respir J. 2023;61:2202389.
    PubMed    


  86. SCHNEIDER S, Poglitsch K, Morgenstern C, Quint T, et al
    Dupilumab increases aspirin tolerance in NSAID-exacerbated respiratory disease.
    Eur Respir J. 2023;61:2201335.
    PubMed     Abstract available


  87. NOBLE PB, Donovan GM
    If your patient with asthma wheezes when sitting or lying quietly, lung function testing may reveal small airway disease.
    Eur Respir J. 2023;61:2202307.
    PubMed    


  88. CORREN J, Brightling CE, Boulet LP, Porsbjerg C, et al
    Not just an anti-eosinophil drug: tezepelumab treatment for type 2 asthma and beyond.
    Eur Respir J. 2023;61:2202202.
    PubMed    


  89. BOULET LP, Boulay ME, Cote A, FitzGerald JM, et al
    Airway inflammation and hyperresponsiveness in subjects with respiratory symptoms and normal spirometry.
    Eur Respir J. 2023;61:2201194.
    PubMed     Abstract available


    February 2023
  90. GAUVREAU GM, Hohlfeld JM, FitzGerald MJ, Boulet LP, et al
    Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma.
    Eur Respir J. 2023 Feb 23:2201193. doi: 10.1183/13993003.01193-2022.
    PubMed     Abstract available


  91. ABDO M, Kirsten AM, von Mutius E, Kopp M, et al
    Minimal Clinically Important Difference for Impulse Oscillometry in Adults with Asthma.
    Eur Respir J. 2023 Feb 9:2201793. doi: 10.1183/13993003.01793-2022.
    PubMed     Abstract available


  92. SAVOURE M, Bousquet J, Leynaert B, Renuy A, et al
    Rhinitis phenotypes and multimorbidities in the general population: the CONSTANCES cohort.
    Eur Respir J. 2023;61:2200943.
    PubMed     Abstract available


    January 2023
  93. POLLOCK J, Chalmers JD
    Aspergillus sensitisation: an underappreciated treatable trait in airway disease.
    Eur Respir J. 2023;61:2202042.
    PubMed    


  94. FAWCETT KA
    Seeing the trees for the wood: reducing heterogeneity in genomic studies of asthma.
    Eur Respir J. 2023;61:2201931.
    PubMed    


    December 2022
  95. DAVIES D, Hyland ME, Lanario JW, Jones RC, et al
    Moving towards patient-centred outcomes: the Severe Asthma Questionnaire.
    Eur Respir J. 2022 Dec 30:2202305. doi: 10.1183/13993003.02305-2022.
    PubMed    


  96. RATTU A, Khaleva E, Brightling C, Dahlen SE, et al
    Identifying and appraising outcome measures for severe asthma: a systematic review.
    Eur Respir J. 2022 Dec 22:2201231. doi: 10.1183/13993003.01231-2022.
    PubMed     Abstract available


  97. KOCKS J, van der Molen T, Voorham J, Baldi S, et al
    Development of a tool to detect small airways dysfunction in asthma clinical practice.
    Eur Respir J. 2022 Dec 14:2200558. doi: 10.1183/13993003.00558-2022.
    PubMed     Abstract available


  98. HAHN DL, Webley W
    U-BIOPRED/BIOAIR proteins: inflammation or infection?
    Eur Respir J. 2022;60:2200571.
    PubMed    


  99. SPARREMAN MIKUS M, Kolmert J, Andersson LI, Dahlen SE, et al
    Reply: U-BIOPRED/BIOAIR proteins: inflammation or infection?
    Eur Respir J. 2022;60:2201795.
    PubMed    


  100. MENZIES-GOW A, Gurnell M, Heaney LG, Corren J, et al
    Adrenal function recovery after durable oral corticosteroid sparing with benralizumab in the PONENTE study.
    Eur Respir J. 2022;60:2103226.
    PubMed     Abstract available


    November 2022
  101. CHERIAN M, Magner KMA, Whitmore GA, Vandemheen KL, et al
    Patient and physician factors associated with symptomatic undiagnosed asthma or COPD.
    Eur Respir J. 2022 Nov 3. pii: 13993003.01721-2022.
    PubMed     Abstract available


  102. BUSSE WW
    Improving systemic corticosteroid stewardship in asthma.
    Eur Respir J. 2022;60.
    PubMed    


  103. PARK JS, Cho YJ, Yun JY, Lee HJ, et al
    Leukotriene receptor antagonists and risk of neuropsychiatric events in children, adolescents and young adults: a self-controlled case series.
    Eur Respir J. 2022;60.
    PubMed     Abstract available


  104. PETSKY H
    Randomised controlled trials utilising F ENO to manage asthma: is it time to acknowledge that "one size does not fit all"?
    Eur Respir J. 2022;60.
    PubMed    


  105. ROBERTS G
    Is it time to consider allergen immunotherapy earlier in the management of allergic asthma?
    Eur Respir J. 2022;60.
    PubMed    


    October 2022
  106. KHALEVA E, Rattu A, Brightling C, Bush A, et al
    Development of Core Outcome Measures sets for paediatric and adult Severe Asthma (COMSA).
    Eur Respir J. 2022 Oct 13. pii: 13993003.00606-2022.
    PubMed     Abstract available


  107. POLVERINO F, Marin JM
    The lower respiratory tract: the hot spot for chronic fixed airflow limitation.
    Eur Respir J. 2022;60.
    PubMed    


    September 2022
  108. PERSSON C
    Creola bodies and pathogenesis of childhood asthma.
    Eur Respir J. 2022 Sep 30. pii: 13993003.01204-2022.
    PubMed    


  109. COLEMAN C, Khaleva E, Rattu A, Frankemolle B, et al
    Narrative Review to capture patients' perceptions and opinions about non-response and response to biological therapy for severe asthma.
    Eur Respir J. 2022 Sep 14. pii: 13993003.00837-2022.
    PubMed     Abstract available


  110. LIU J, Bowatte G, Pham J, Perret JL, et al
    Pre-pubertal smoke exposure of fathers and increased risk of offspring asthma: a possible transgenerational effect.
    Eur Respir J. 2022 Sep 14. pii: 13993003.00257-2022.
    PubMed    


  111. SORIANO JB
    Planetary respiratory health for asthma, rhinoconjunctivitis and eczema.
    Eur Respir J. 2022;60.
    PubMed    


  112. CHAN JSK, Murray RB, Price D
    Oral corticosteroids in asthma and beyond: moving forward.
    Eur Respir J. 2022;60.
    PubMed    


  113. PERREM L, Subbarao P
    Moving the dial on identifying endotypes of asthma from early life.
    Eur Respir J. 2022;60.
    PubMed    



  114. "Crucial role for lung iron level and regulation in the pathogenesis and severity of asthma." M.K. Ali, R.Y. Kim, A.C. Brown et al. Eur Respir J 2020; 55: 1901340.
    Eur Respir J. 2022;60.
    PubMed    


  115. PAVORD ID
    Case-finding and diagnosis of obstructive airway diseases: the Dragons' Den experience.
    Eur Respir J. 2022;60.
    PubMed    


    August 2022
  116. CHAN R, Lipworth B
    Interactions between spirometry and oscillometry in patients with moderate to severe asthma.
    Eur Respir J. 2022 Aug 18. pii: 13993003.00543-2022.
    PubMed    


  117. LEE S, Prokopenko D, Kelly RS, Lutz S, et al
    Zinc finger protein 33B demonstrates sex-interaction with atopy-related markers in childhood asthma.
    Eur Respir J. 2022 Aug 11. pii: 13993003.00479-2022.
    PubMed     Abstract available


    July 2022
  118. PERRET JL, Dharmage SC, Bui DS
    Early life respiratory infections and pre-adult asthma: could there be an interaction and differential misclassification?
    Eur Respir J. 2022 Jul 26. pii: 13993003.01141-2022.
    PubMed    


  119. MCLOUGHLIN RF, Clark VL, Urroz PD, Gibson PG, et al
    Increasing physical activity in severe asthma: a systematic review and meta-analysis.
    Eur Respir J. 2022 Jul 26. pii: 13993003.00546-2022.
    PubMed     Abstract available


  120. VAN MEEL ER, Duijts L
    Reply to: "Early-life respiratory infections and pre-adult asthma: could there be an interaction and differential misclassification?"
    Eur Respir J. 2022 Jul 26. pii: 13993003.01384-2022.
    PubMed    


  121. MURPHY VE, Jensen ME, Holliday EG, Giles WB, et al
    Effect of asthma management with exhaled nitric oxide versus usual care on perinatal outcomes.
    Eur Respir J. 2022 Jul 1. pii: 13993003.00298-2022.
    PubMed     Abstract available


  122. REDMOND C, Heaney LG, Chaudhuri R, Jackson DJ, et al
    Benefits of specialist severe asthma management: demographic and geographic disparities.
    Eur Respir J. 2022 Jul 1. pii: 13993003.00660-2022.
    PubMed     Abstract available


  123. HOLMES J, McGarvey LP, Birring SS, Fletcher H, et al
    An observational study to determine the relationship between cough frequency and markers of inflammation in severe asthma.
    Eur Respir J. 2022 Jul 1. pii: 13993003.03205-2021.
    PubMed     Abstract available


  124. SALTER B, Zhao N, Son K, Suray Tan N, et al
    Airway autoantibodies are determinants of asthma severity.
    Eur Respir J. 2022 Jul 1. pii: 13993003.00442-2022.
    PubMed     Abstract available


  125. WURZEL D, Licciardi PV
    Targeted strategies are needed to prevent childhood asthma.
    Eur Respir J. 2022;60.
    PubMed    


  126. WARK PAB
    We need to understand why viral infections lead to acute asthma.
    Eur Respir J. 2022;60.
    PubMed    


  127. VAN HULST G, Jorssen J, Jacobs N, Henket M, et al
    Reply: Ex vivo SOCS3 gene responsiveness to alarmins in eosinophils of mepolizumab-treated patients is as yet of unknown biological significance.
    Eur Respir J. 2022;60.
    PubMed    


  128. COUILLARD S
    The alarmin(g) effect of interleukin-5 blockade on residual eosinophil function is of clinical consequence.
    Eur Respir J. 2022;60.
    PubMed    


    June 2022

  129. "International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma." Kian Fan Chung, Sally E. Wenzel, Jan L. Brozek, et al. Eur Respir J 2014; 43: 343-373.
    Eur Respir J. 2022;59.
    PubMed    


  130. BATEMAN ED, Price DB, Wang HC, Schonffeldt P, et al
    Reply to: Cause or consequence?
    Eur Respir J. 2022;59.
    PubMed    


  131. VOLPE FM
    Cause or consequence?
    Eur Respir J. 2022;59.
    PubMed    


    May 2022
  132. WOEHLK C, Von Bulow A, Ghanizada M, Baastrup Sondergaard M, et al
    Allergen immunotherapy effectively reduces the risk of exacerbations and lower respiratory tract infections in both seasonal and perennial allergic asthma: a nationwide epidemiological study.
    Eur Respir J. 2022 May 26. pii: 13993003.00446-2022.
    PubMed     Abstract available


  133. SUN Y, Zhang M, Ou Z, Meng Y, et al
    Indoor microbiome, microbial and plant metabolites, chemical compounds and asthma symptoms in junior high school students: a multicentre association study in Malaysia.
    Eur Respir J. 2022 May 26. pii: 13993003.00260-2022.
    PubMed     Abstract available


  134. HUMBERT M, Bourdin A, Taille C, Kamar D, et al
    Real-life omalizumab exposure and discontinuation in a large nationwide population-based study of pediatric and adult asthmatics.
    Eur Respir J. 2022 May 26. pii: 13993003.03130-2021.
    PubMed     Abstract available


  135. HABENER A, Grychtol R, Gaedcke S, DeLuca D, et al
    IgA(+) memory B cells are significantly increased in patients with asthma and small airways dysfunction.
    Eur Respir J. 2022 May 20. pii: 13993003.02130-2021.
    PubMed     Abstract available


  136. KROES JA, Zielhuis SW, De Jong K, Hashimoto S, et al
    Cumulative Corticosteroid Sparing Effect of Anti-Interleukin-5/5Ra In Eosinophilic Asthma.
    Eur Respir J. 2022 May 20. pii: 13993003.02983-2021.
    PubMed     Abstract available


  137. GAIETTO K, Han YY, Forno E, Bacharier LB, et al
    Violence-related distress and lung function in two longitudinal studies of youth.
    Eur Respir J. 2022;59.
    PubMed     Abstract available


    April 2022
  138. RABE KF, Pavord ID, Castro M, Wechsler ME, et al
    Dupilumab efficacy and safety in patients with asthma and blood eosinophils >/=500 cells.microL(-1).
    Eur Respir J. 2022 Apr 29. pii: 13993003.02577-2021.
    PubMed    


  139. VAN MEEL ER, Mensink-Bout SM, den Dekker HT, Ahluwalia TS, et al
    Early-life respiratory tract infections and the risk of school-age lower lung function and asthma: a meta-analysis of 150 000 European children.
    Eur Respir J. 2022 Apr 29. pii: 13993003.02395-2021.
    PubMed     Abstract available


  140. MENSINK-BOUT SM, van Meel ER, de Jongste JC, Annesi-Maesano I, et al
    Maternal diet in pregnancy and child's respiratory outcomes: an individual participant data meta-analysis of 18 000 children.
    Eur Respir J. 2022;59.
    PubMed     Abstract available


  141. SINGH D, Beier J, Astbury C, Belvisi MG, et al
    The novel bronchodilator navafenterol: a phase 2a, multicentre, randomised, double-blind, placebo-controlled crossover trial in COPD.
    Eur Respir J. 2022;59.
    PubMed     Abstract available


    March 2022
  142. THOMAS D, McDonald VM, Pavord ID, Gibson PG, et al
    Asthma remission- what is it and how can it be achieved?
    Eur Respir J. 2022 Mar 31. pii: 13993003.02583-2021.
    PubMed     Abstract available


  143. HUYNH C, Whitmore GA, Vandemheen KL, FitzGerald JM, et al
    Derivation and Validation of the UCAP-Q Case-finding Questionnaire to Detect Undiagnosed Asthma and COPD.
    Eur Respir J. 2022 Mar 24. pii: 13993003.03243-2021.
    PubMed     Abstract available


  144. HAN YY, Yan Q, Chen W, Celedon JC, et al
    Child maltreatment, anxiety and depression, and asthma among British adults in the UK Biobank.
    Eur Respir J. 2022 Mar 17. pii: 13993003.03160-2021.
    PubMed     Abstract available


  145. BAL C, Idzko M, Skrgat S, Koch A, et al
    FeNO is associated with disease burden in the German Asthma Net severe asthma cohort.
    Eur Respir J. 2022 Mar 10. pii: 13993003.01233-2021.
    PubMed    


  146. KLEIN DK, Silberbrandt A, Frossing L, Hvidtfeldt M, et al
    Impact of former smoking exposure on airway eosinophilic activation and autoimmunity in patients with severe asthma.
    Eur Respir J. 2022 Mar 2. pii: 13993003.02446-2021.
    PubMed     Abstract available


  147. VONK JM, Roukema J
    Air pollution susceptibility in children with asthma and obesity: tidal volume as key player?
    Eur Respir J. 2022;59.
    PubMed    


  148. THAMRIN C, Robinson PD, Farah CS, King GG, et al
    Technical standards for respiratory oscillometry and bronchodilator response cut-offs.
    Eur Respir J. 2022;59.
    PubMed    


  149. DAGHER R, Kumar V, Copenhaver AM, Gallagher S, et al
    Novel mechanisms of action contributing to benralizumab's potent anti-eosinophilic activity.
    Eur Respir J. 2022;59.
    PubMed     Abstract available


    February 2022
  150. MAISON N, Omony J, Illi S, Thiele D, et al
    T-high asthma phenotypes across life span.
    Eur Respir J. 2022 Feb 24. pii: 13993003.02288-2021.
    PubMed     Abstract available


  151. ALI GB, Lowe AJ, Perret JL, Walters EH, et al
    Impact of lifetime body mass index trajectories on the incidence and persistence of adult asthma.
    Eur Respir J. 2022 Feb 24. pii: 13993003.02286-2021.
    PubMed     Abstract available


  152. MORTIMER K, Reddel HK, Pitrez PM, Bateman ED, et al
    Asthma management in low- and middle-income countries: case for change.
    Eur Respir J. 2022 Feb 24. pii: 13993003.03179-2021.
    PubMed     Abstract available


  153. MORTIMER K, Lesosky M, Garcia-Marcos L, Innes Asher M, et al
    The burden of asthma, hay fever and eczema in adults in 17 countries: GAN Phase I study.
    Eur Respir J. 2022 Feb 24. pii: 13993003.02865-2021.
    PubMed     Abstract available


  154. MOSLEMI A, Kontogianni K, Brock J, Wood S, et al
    Differentiating COPD and Asthma using Quantitative CT Imaging and Machine Learning.
    Eur Respir J. 2022 Feb 24. pii: 13993003.03078-2021.
    PubMed     Abstract available


  155. LOUIS R, Satia I, Ojanguren I, Schleich F, et al
    European Respiratory Society Guidelines for the Diagnosis of Asthma in Adults.
    Eur Respir J. 2022 Feb 15. pii: 13993003.01585-2021.
    PubMed     Abstract available


  156. SKOV IR, Madsen H, Henriksen DP, Andersen JH, et al
    Low dose oral corticosteroids in asthma associates with increased morbidity and mortality.
    Eur Respir J. 2022 Feb 10. pii: 13993003.03054-2021.
    PubMed     Abstract available


  157. GARCIA-MARCOS L, Innes Asher M, Pearce N, Ellwood E, et al
    The burden of asthma, hay fever and eczema in children in 25 countries: GAN Phase I study.
    Eur Respir J. 2022 Feb 10. pii: 13993003.02866-2021.
    PubMed     Abstract available


  158. TAYTARD J, Koskas M, Beydon N
    Spirometry forced expiratory time is driven by airflow limitation in asthmatic children.
    Eur Respir J. 2022 Feb 10. pii: 13993003.02620-2021.
    PubMed    


  159. MARCON A, Locatelli F, Accordini S
    The coexistence of asthma and COPD: some considerations about prevalence and lung function decline.
    Eur Respir J. 2022 Feb 3. pii: 13993003.00096-2022.
    PubMed    


  160. KEARNS N, Bruce P, Williams M, Doppen M, et al
    Repeated dose budesonide/formoterol compared to salbutamol in adult asthma: A randomised cross-over trial.
    Eur Respir J. 2022 Feb 3. pii: 13993003.02309-2021.
    PubMed     Abstract available


  161. SEYS SF, Long MB
    The quest for biomarkers in asthma: challenging the T2 versus non-T2 paradigm.
    Eur Respir J. 2022;59.
    PubMed    


    January 2022
  162. PARASKAKIS E, Sarikloglou E, Fouzas S, Steiropoulos P, et al
    Improved prediction of asthma exacerbations by measuring distal airway inflammation.
    Eur Respir J. 2022 Jan 27. pii: 13993003.01684-2021.
    PubMed    


  163. GAUVREAU GM, Davis BE, Scadding G, Boulet LP, et al
    Allergen Provocation Tests in Respiratory Research: Building on 50 Years of Experience.
    Eur Respir J. 2022 Jan 27. pii: 13993003.02782-2021.
    PubMed     Abstract available


  164. RICCARDI D, Ward JP, Yarova PL, Janssen LJ, et al
    Topical therapy with negative allosteric modulators of the calcium-sensing receptor (calcilytics) for the management of asthma: the beginning of a new era?
    Eur Respir J. 2022 Jan 20. pii: 13993003.02103-2021.
    PubMed     Abstract available


  165. AL-SHAIKHLY T, Murphy RC, Parker A, Lai Y, et al
    Location of eosinophils in the airway wall is critical for specific features of airway hyperresponsiveness and T2 inflammation in asthma.
    Eur Respir J. 2022 Jan 13. pii: 13993003.01865-2021.
    PubMed     Abstract available


  166. PEROTIN JM, Wheway G, Tariq K, Azim A, et al
    Vulnerability to acid reflux of the airway epithelium in severe asthma.
    Eur Respir J. 2022 Jan 7. pii: 13993003.01634-2021.
    PubMed     Abstract available


  167. RAMIS J, Middlewick R, Pappalardo F, Cairns JT, et al
    Lysyl oxidase-like 2 is increased in asthma and contributes to asthmatic airway remodelling.
    Eur Respir J. 2022 Jan 7. pii: 13993003.04361-2020.
    PubMed     Abstract available


  168. BENSON VS, Hartl S, Barnes N, Galwey N, et al
    Blood eosinophil counts in the general population and airways disease: a comprehensive review and meta-analysis.
    Eur Respir J. 2022;59.
    PubMed     Abstract available


    December 2021
  169. RAITA Y, Perez-Losada M, Freishtat RJ, Hahn A, et al
    Nasopharyngeal metatranscriptome profiles of infants with bronchiolitis and risk of childhood asthma: a multicentre prospective study.
    Eur Respir J. 2021 Dec 16. pii: 13993003.02293-2021.
    PubMed     Abstract available


  170. PORSBJERG C, Nieto-Fontarigo JJ, Cerps S, Ramu S, et al
    Phenotype and severity of asthma determines bronchial epithelial immune responses to a viral mimic.
    Eur Respir J. 2021 Dec 16. pii: 13993003.02333-2021.
    PubMed     Abstract available


  171. AGARWAL R, Muthu V
    Prednisolone plus itraconazole in acute-stage allergic bronchopulmonary aspergillosis complicating asthma.
    Eur Respir J. 2021 Dec 9. pii: 13993003.02989-2021.
    PubMed    


  172. HAVETTE A, Regard L, Roche N, Burgel PR, et al
    Prednisolone plus itraconazole in acute-stage allergic bronchopulmonary aspergillosis complicating asthma: is the benefit worth the risk?
    Eur Respir J. 2021 Dec 9. pii: 13993003.02924-2021.
    PubMed    


  173. KRUIZINGA MD, Essers E, Stuurman FE, Yavuz Y, et al
    Clinical validation of digital biomarkers for pediatric patients with asthma and cystic fibrosis - Potential for clinical trials and clinical care.
    Eur Respir J. 2021 Dec 9. pii: 13993003.00208-2021.
    PubMed     Abstract available


  174. GURDENIZ G, Ernst M, Rago D, Kim M, et al
    Neonatal metabolome of cesarean section and risk of childhood asthma.
    Eur Respir J. 2021 Dec 9. pii: 13993003.02406-2021.
    PubMed     Abstract available


  175. RYAN D, Sabroe I
    Identifying and addressing health inequalities in asthma care.
    Eur Respir J. 2021;58.
    PubMed    


  176. PAPAIOANNOU AI, Photiades A, Gaga M
    Using placebo-controlled trials to define predictors of future exacerbations in severe asthma patients.
    Eur Respir J. 2021;58.
    PubMed    


  177. PARK S, Lee S, Kim Y, Cho S, et al
    Kidney function and obstructive lung disease: a bidirectional Mendelian randomisation study.
    Eur Respir J. 2021;58.
    PubMed     Abstract available


    November 2021
  178. ABDEL-AZIZ MI, Vijverberg SJH, Neerincx AH, Brinkman P, et al
    A multi-omics approach to delineate sputum microbiome-associated asthma inflammatory phenotypes.
    Eur Respir J. 2021 Nov 25. pii: 13993003.02603-2021.
    PubMed    


  179. REINKE SN, Naz S, Chaleckis R, Gallart-Ayala H, et al
    Urinary metabotype of severe asthma evidences decreased carnitine metabolism independent of oral corticosteroid treatment in the U-BIOPRED study.
    Eur Respir J. 2021 Nov 25. pii: 13993003.01733-2021.
    PubMed     Abstract available


  180. MIKUS MS, Kolmert J, Andersson LI, Ostling J, et al
    Plasma proteins elevated in severe asthma despite oral steroid use and unrelated to Type-2 inflammation.
    Eur Respir J. 2021 Nov 4. pii: 13993003.00142-2021.
    PubMed     Abstract available


  181. OLIVER BG
    Food for thought: why is there more airway smooth muscle in asthma?
    Eur Respir J. 2021;58.
    PubMed    


  182. MANNINO DM
    Asthma, COPD and their overlap: coexistence or something more?
    Eur Respir J. 2021;58.
    PubMed    


    October 2021
  183. PIJNENBURG MW, Frey U, De Jongste JC, Saglani S, et al
    Childhood asthma- pathogenesis and phenotypes.
    Eur Respir J. 2021 Oct 28. pii: 13993003.00731-2021.
    PubMed     Abstract available


  184. ELSEY L, Pantin T, Holmes LJ, Tavernier G, et al
    Outcomes over the first two years of treatment with mepolizumab in severe asthma.
    Eur Respir J. 2021 Oct 28. pii: 13993003.01313-2021.
    PubMed     Abstract available


  185. REDDEL HK, Bacharier LB, Bateman ED, Brightling CE, et al
    Global Initiative for Asthma (GINA) Strategy 2021 - Executive summary and rationale for key changes.
    Eur Respir J. 2021 Oct 19. pii: 13993003.02730-2021.
    PubMed     Abstract available


  186. CHAN R, Misirovs R, Lipworth B
    Repeatability of impulse oscillometry in patients with severe asthma.
    Eur Respir J. 2021 Oct 8. pii: 13993003.01679-2021.
    PubMed    


  187. SUN Y, Xia PF, Xie J, Mustieles V, et al
    Association of blood trihalomethane concentrations with asthma in U.S. adolescents: nationally representative cross-sectional study.
    Eur Respir J. 2021 Oct 8. pii: 13993003.01440-2021.
    PubMed     Abstract available


  188. PORSBJERG C, Maitland-van der Zee AH, Brusselle G, Canonica GW, et al
    3TR: a pan-European cross-disease research consortium aimed at improving personalised biological treatment of asthma and COPD.
    Eur Respir J. 2021;58.
    PubMed    


    September 2021
  189. MIURA S, Iwamoto H, Omori K, Yamaguchi K, et al
    Accelerated decline in lung function in adults with a history of remitted childhood asthma.
    Eur Respir J. 2021 Sep 29. pii: 13993003.00305-2021.
    PubMed     Abstract available


  190. BATEMAN ED, Price DB, Wang HC, Khattab A, et al
    Short-acting beta2-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study.
    Eur Respir J. 2021 Sep 24. pii: 13993003.01402-2021.
    PubMed     Abstract available


  191. BUSBY J, Matthews JG, Chaudhuri R, Pavord ID, et al
    Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthma.
    Eur Respir J. 2021 Sep 24. pii: 13993003.00768-2021.
    PubMed     Abstract available


  192. PANAGOU P, Tzilas V, Bouros D
    "Dynamic (C dyn) lung compliance in non-smokers with asthma and fixed, non-reversible airflow obstruction" ERJ 2021 58: 2004400.
    Eur Respir J. 2021 Sep 24. pii: 13993003.02361-2021.
    PubMed    


    April 2021
  193. ESTEVES P, Blanc L, Celle A, Dupin I, et al
    Crucial role of fatty acid oxidation in asthmatic bronchial smooth muscle remodelling.
    Eur Respir J. 2021 Apr 8. pii: 13993003.04252-2020.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Asthma is free of charge.